Previous close | 2.4100 |
Open | 2.7700 |
Bid | 3.1900 x 100 |
Ask | 0.0000 x 0 |
Day's range | 2.5901 - 4.0899 |
52-week range | 2.0900 - 42.0000 |
Volume | |
Avg. volume | 105,701 |
Market cap | 6.527M |
Beta (5Y monthly) | -0.54 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
GENPREX (GNPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.